Tejon Ranch Co.
NYSE:TRCConglomerates
-$0.06 today
- Market cap
- $462.56M
- Beta
- 0.59
- P/E (TTM)
- 296.5
- EPS (TTM)
- $0.06
Volume 0.16M
Average 0.09M
TRC EBITDA Margin
EBITDA as a percentage of revenue.
Tejon Ranch Co.NYSE: TRC
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 35.2%
EBITDA Margin was 35.2% in Q1 FY2026, up 56.2 pp from a year earlier. On a trailing-twelve-month basis it was 27.8%, up 9.8 pp year over year. Over 3 fiscal years it narrowed by 20.7 pp.
Context
- EBITDA Margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 1 analysts of 33.2% for the fiscal year ending Dec 2026, up from 14.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 35.2%-5.4 pp QoQ
- Last fiscal yearDec 2025
- 14.5%-5.9 pp YoY
- LTMMar 2026
- 27.8%+9.8 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +56.2 pp | +26.4 pp | -29.9 pp |
| 1 year | -5.9 pp | +18.8 pp | +24.7 pp |
| 3 years | -20.7 pp | — | — |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 14.5%
- Year-over-year change
- -5.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.5% | -5.9pp |
| FY2024 | 2024-12-31 | 20.4% | -2.8pp |
| FY2023 | 2023-12-31 | 23.2% | -11.9pp |
| FY2022 | 2022-12-31 | 35.1% | +10.4pp |
| FY2021 | 2021-12-31 | 24.7% | — |
EBITDA Margin vs competitors
How TRC compares with its peers on the latest reported figures
- TRC's LTM Mar 2026 EBITDA Margin of 27.8% is the 2nd highest of the 9 companies compared; the peer median is 0.6%.
- Its year-over-year change of +9.8 pp is the highest of 9, against a peer median of -4.5 pp.
- Over three fiscal years its change of -20.7 pp compares with a peer median of +1.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 76.5% | -0.5 pp | +8.2 pp | |
| LTM Mar 2026 | 27.8% | +9.8 pp | -20.7 pp | |
| LTM Apr 2026 | 5.3% | -11.4 pp | -10.4 pp | |
| LTM Mar 2026 | 4.3% | +0.1 pp | +3.5 pp | |
| LTM Mar 2026 | 1.6% | -8.5 pp | -3.8 pp | |
| LTM Apr 2026 | -0.4% | -12.1 pp | -17.3 pp | |
| LTM Mar 2026 | -0.5% | +1.0 pp | +3.3 pp | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | -2.7% | +5.5 pp | +8.6 pp |
| LTM Mar 2026 | -77.4% | -542.7 pp | -1.4 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding TRC) | 0.6% | -4.5 pp | +1.0 pp | |
Competitors are the stored peer set for TRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.61M | 79.22M | 44.74M | 41.89M | 49.59M |
| Cost of Revenue | 46.03M | 55.79M | 38.57M | 39.99M | 43.48M |
| Gross Profit | 9.58M | 23.43M | 6.17M | 1.89M | 6.11M |
| Gross Margin | 17.2% | 29.6% | 13.8% | 4.5% | 12.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 9.84M | 9.7M | 0 | 11.09M | 0 |
| Operating Expenses | 9.84M | 9.7M | 9.87M | 11.09M | 14.07M |
| Depreciation & Amortization | 4.59M | 4.63M | 4.81M | 4.89M | 6.01M |
| EBITDA | 13.76M | 27.83M | 10.39M | 8.55M | 7.17M |
| EBITDA Margin | 24.7% | 35.1% | 23.2% | 20.4% | 14.5% |
| Operating Income | (260K) | 13.73M | (3.7M) | (9.2M) | (7.95M) |
| Operating Margin | -0.5% | 17.3% | -8.3% | -22.0% | -16.0% |
| Interest Income | 0 | 0 | 0 | 2.27M | 914K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 9.42M | 9.47M | 9.29M | 12.86M | 9.11M |
| Income Before Tax | 9.16M | 23.2M | 5.59M | 3.66M | 1.16M |
| Pre-Tax Margin | 16.5% | 29.3% | 12.5% | 8.7% | 2.3% |
| Income Tax Expense | 3.82M | 7.39M | 2.32M | 976K | 1.09M |
| Net Income | 5.35M | 15.81M | 3.27M | 2.69M | 75K |
| Net Margin | 9.6% | 20.0% | 7.3% | 6.4% | 0.2% |
| EPS (Basic) | 0.20 | 0.60 | 0.12 | 0.10 | 0.00 |
| EPS (Diluted) | 0.20 | 0.59 | 0.12 | 0.10 | 0.00 |
| Weighted Avg Shares | 26.34M | 26.48M | 26.71M | 26.81M | 26.95M |
| Weighted Avg Shares (Diluted) | 26.41M | 26.65M | 26.71M | 26.82M | 26.95M |
Tejon Ranch Co.
NYSE:TRC
Intrinsic Alpha fair value
Locked
Current Price
$17.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.